‘Historic Action’: FDA Approves First CAR-T Therapy – Regulatory Focus
|
‘Historic Action’: FDA Approves First CAR–T Therapy
Regulatory Focus In addition to Kymriah’s approval, FDA also announced the expanded approval of Roche’s Actemra (tocilizumab) to treat CAR T-cell-induced severe or life-threatening cytokine release syndrome in patients 2 years of age or older. “In clinical trials in … |
KRVS |
FDA Approves First Gene Therapy Treatment For Cancer
KRVS The Food and Drug Administration Wednesday announced what the agency calls a “historic action” — the first approval of a gene therapy in the United States. The FDA approved Kymriah, which scientists refer to as a “living drug” because it involves … |
GenomeWeb |
Let the CRISPR Games Begin! | GenomeWeb
GenomeWeb Researchers at the Stanford University School of Medicine have launched a new level for the online computer game Eterna, in which they’re asking players to … Researchers challenge video game players to design CRISPR …UPI.com |
KASU |
FDA Approves First Gene Therapy Treatment For Cancer
KASU The Food and Drug Administration Wednesday announced what the agency calls a “historic action” — the first approval of a gene therapy in the United States. The FDA approved Kymriah, which scientists refer to as a “living drug” because it involves … |
Cancer Therapy Advisor |
FDA Approves CAR–T Therapy Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia
Cancer Therapy Advisor This approval marks the first chimeric antigen receptor T cell (CAR-T) therapy, which utilizes the patients’ own genetically-modified T–cells to target the CD19 antigen on the surface of leukemia cells. Once modified, the cells are injected back into … |
Cancer Therapy Advisor |
FDA Approves CAR–T Therapy Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia
Cancer Therapy Advisor This approval marks the first chimeric antigen receptor T cell (CAR-T) therapy, which utilizes the patients’ own genetically-modified T–cells to target the CD19 antigen on the surface of leukemia cells. Once modified, the cells are injected back into … |
Cancer Therapy Advisor |
FDA Approves CAR–T Therapy Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia
Cancer Therapy Advisor This approval marks the first chimeric antigen receptor T cell (CAR-T) therapy, which utilizes the patients’ own genetically-modified T–cells to target the CD19 antigen on the surface of leukemia cells. Once modified, the cells are injected back into … |
|
FDA approves revolutionary new cell-modifying cancer treatment
The Week Magazine On Wednesday, the Food and Drug Administration approved a revolutionary new type of cancer treatment that genetically modifies the body’s own cells. The treatment, known as CAR–T therapy, is the first type of gene therapy approved in the U.S and will … |